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The objective of this study was to investigate expression of various growth factors associated with angiogenesis and
lymphangiogenesis and of their receptors in ductal carcinomas in situ of the breast (DCIS). We studied protein expression of
basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF)-A, endothelin (ET)-1, and VEGF-C, and their
receptors bFGF-R1, Flt-1, KDR, ETAR, ETBR, and Flt-4 immunohistochemically in 200 DCIS (pure DCIS: n¼96; DCIS adjacent to an
invasive component: n¼104) using self-constructed tissue microarrays. Basic fibroblast growth factor-R1, VEGF-C, Flt-4, and ETAR
were expressed in the tumour cells in the majority of cases, whereas bFGF and Flt-1 expression was rarely observed. VEGF-A, KDR,
ET-1, and ETBR were variably expressed. The findings of VEGF-C and its receptor Flt-4 as lymphangiogenic factors being expressed in
tumour cells of nearly all DCIS lesions and the observed expression of various angiogenic growth factors in most DCIS suggest that in
situ carcinomas are capable of inducing angiogenesis and lymphangiogenesis. Moreover, we found a higher angiogenic activity in pure
DCIS as compared to DCIS with concomitant invasive carcinoma. This association of angiogenic factors with pure DCIS was
considerably more pronounced in the subgroup of non-high-grade DCIS (n¼103) as compared with high-grade DCIS (n¼94).
Determination of these angiogenic markers may therefore facilitate discrimination between biologically different subgroups of DCIS
and could help to identify a particularly angiogenic subset with a potentially higher probability of recurrence or of progression to
invasiveness. For these DCIS, targeting angiogenesis may represent a feasible therapeutic approach for prevention of progression of
DCIS to invasion.
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Angiogenesis is known to be a prerequisite for tumour growth
beyond a few mm
3 in size (Folkman, 1995). Several studies have
shown that the angiogenic potential as assessed by tumour
microvessel density (MVD) of breast carcinomas correlates with
tumour progression and metastasis, thus predicting a poor clinical
outcome in breast cancer patients (Gasparini et al, 1994; Heimann
et al, 1996). Also, lymphangiogenesis in breast cancer is supposed
to contribute to tumour progression and poor survival by
predisposing to metastatic spread via the lymphatic system
(Nakamura et al, 2003).
The family of vascular endothelial growth factor (VEGF)
proteins is a group of angiogenic factors that regulate the growth
of endothelial cells. There are four major VEGF isoforms, VEGF-A,
VEGF-B, VEGF-C, and VEGF-D. Three main tyrosine-kinase
receptors (RTKs) have been identified: VEGFR-1 (also known as
Flt-1) (de Vries et al, 1992), VEGFR-2 (also known as Flk-1 in
mouse or KDR in human) (Millauer et al, 1993), and VEGFR-3
(also known as Flt-4) (Pajusola et al, 1994).
Vascular endothelial growth factor-A is considered to be the
most crucial regulator of angiogenesis and vasculogenesis (Ferrara
et al, 2003) and its expression has been demonstrated in cancer
cells of various human tumours including breast cancer (Yoshiji
et al, 1996; De Jong et al, 1998a). In breast carcinomas, VEGF-A
expression correlates with angiogenesis and seems to represent a
useful prognostic marker for poor outcome (Obermaier et al, 1997;
Gasparini, 2001). The biological effects of VEGF-A are mediated by
Flt-1 and KDR binding VEGF-A with high affinity (Mustonen and
Alitalo 1995). Although Flt-1 was the first receptor to be identified
as a VEGF receptor (de Vries et al, 1992), there is much evidence
that Flt-1 performs an inhibitory role in mitogenesis of endothelial
cells by sequestering VEGF-A and preventing its interaction with
KDR, whereas KDR is considered to be the major mediator of
angiogenesis (Ferrara et al, 2003). Initially, expression of Flt-1 and
KDR was believed to be restricted to the vascular endothelium, but
to date these receptors have also been detected in several types of
nonendothelial cells including breast cancer cells, suggesting an
autocrine effect of VEGF-A on tumour cells (De Jong et al, 1998a;
Kranz et al, 1999). The clinical significance of VEGF-A receptor
expression in breast cancer is yet unclear. On the one hand, it has
been reported that Flt-1 overexpression improves survival in
breast cancer, whereas KDR expression is associated with a poor
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demonstrated, Flt-1 to be related to a higher metastatic and local
recurrence risk in breast cancer patients (Dales et al, 2004).
Flt-4 is an RTK that is similar to the two VEGF-A receptors in
structure but primarily represents a marker for lymphatic
endothelial cells and which is also expressed in epithelial cells of
various malignant tissues. Although VEGF-C appears to be the
primary lymphangiogenic factor, it also links angiogenesis with
lymphangiogenesis, as it can stimulate both processes by activating
Flt-4 (Jeltsch et al, 1997) and KDR (Cao et al, 1998), respectively.
Moreover, an autocrine growth stimulation pattern of VEGF-C
via Flt-4 has been suggested in tumours (Van Trappen et al, 2003).
In breast cancer, expression of VEGF-C and Flt-4 is associated
with angiogenesis and lymphangiogenesis (Valtola et al, 1999;
Kinoshita et al, 2001). Also, a clinicopathological significance of
VEGF-C and Flt-4 in breast cancer has been described, since
their expression correlated with lymph node metastasis and
decreased survival of patients (Kinoshita et al, 2001; Nakamura
et al, 2003).
Another category of angiogenic activators evaluated in human
breast carcinomas is the fibroblast growth factor (FGF) family.
FGFs are important signalling molecules contributing to angiogen-
esis, tumour growth, and tumour progression (Mason, 1994; Kern
and Lippman, 1996). Among FGFs, basic FGF (bFGF) which binds
to specific RTKs, FGFRs (Mohammadi et al, 1997), is the most
active growth factor for endothelium and several studies have
demonstrated its expression in breast cancer (Luqmani et al, 1992;
Colomer et al, 1997; Smith et al, 1999). However, the clinical
relevance of bFGF expression in breast cancer is yet unclear, since
conflicting results have been reported (Colomer et al, 1997; Smith
et al, 1999).
Recently, the endothelin (ET)-axis comprising the vasoactive
peptide ET-1 and the cell-surface receptors, ETAR and ETBR, came
into focus due to its emerging role in cancer (Nelson et al, 2003).
Increased ET-1 expression has been demonstrated in various
human malignancies as well as in breast cancer. It appears that the
effects of the ET-axis on tumorigenesis and tumour progression
are mediated by several mechanisms including proliferation,
angiogenesis, and inhibition of apoptosis (Nelson et al, 2003).
Endothelin-1 contributes to the process of angiogenesis, stimulat-
ing endothelial cell growth predominantly through ETBR and
inducing vascular smooth muscle cell and pericyte mitogenesis
mediated through ETAR (Bek and McMillen, 2000; Salani et al,
2000). Previously, we have demonstrated an increased expression
of the ET-axis in breast carcinomas. Expression of ETAR correlated
with aggressive types of breast cancer and poor clinical outcome,
indicating a potential connection between the ET-axis and disease
progression in breast cancer (Wu ¨lfing et al, 2003a). Similar to
findings in ovarian cancer (Salani et al, 2000), we observed a
significant correlation between expression of the ET axis and
neovascularisation and VEGF expression of breast carcinomas
(Wu ¨lfing et al, 2004b). Further studies have suggested that
activation of ETAR by ET-1 induces the production of VEGF,
which in turn stimulates tumour growth and angiogenesis by
increasing the levels of hypoxia-inducible factor-1 (HIF-1a), in a
time- and dose-dependent manner (Spinella et al, 2002).
The switch of a tumour to an angiogenic phenotype is
considered to be critical for progression and metastasis (Folkman
et al, 1989). In DCIS, two distinct vascular patterns have been
described: (1) an increased stromal vascular density which is
thought to result from angiogenic factors being released by
accessory cells; (2) an increase in periductal vessels as an effect of
angiogenic factors secreted by intraductal tumour cells (Guidi
et al, 1994; Engels et al, 1997).
This last pattern has been shown to correlate with the
development of an invasive recurrence (Teo et al, 2003). Thus, it
is conceivable that an increase in periductal angiogenesis may
contribute to the transformation from DCIS to invasive carcinoma.
In the present study, we therefore analysed expression of several
surrogate markers of angiogenesis and lymphangiogenesis in DCIS
using a tissue microarray (TMA) with 902 cores from 200 DCIS
specimens. The objective was to see whether these markers are
associated with established histopathological characteristics and to
assess whether there are different expression patterns between the
groups of DCIS with (n¼104) and without (n¼96) coexistent
invasive carcinoma.
MATERIALS AND METHODS
Patients and tumours
A total of 200 patients with DCIS were included in the study.
Among these, 96 patients had a pure DCIS and in 104 patients the
DCIS was associated with an invasive breast carcinoma (coexistent
DCIS). All cases were classified according to the criteria outlined
by Holland et al (1994) considering the nuclear grading and
architectural features. Based on this classification, cases were
graduated as low grade (n¼54), intermediate grade (n¼49), and
high grade (n¼94). With respect to these criteria, cases were
divided into ‘non-high-grade’ (low grade þ intermediate grade) or
‘high-grade’ DCIS. The median age of patients was 59 years (range
18–94 years).
Breast cancer TMA
Routinely fixed paraffin-embedded tissue blocks containing DCIS
were extracted from the files of pathology laboratories serving as
donor blocks for the TMA. Sections were cut from each donor
block and stained with haematoxylin and eosin. Using these slides
morphologically representative regions were chosen from each of
the 200 tumour samples and circled. At least four cylindrical
0.6mm cores were acquired from the circled areas of each DCIS
sample and precisely arrayed into a new recipient paraffin block
(20 35mm) using a manual tissue arrayer (Beecher Instruments,
Silver Spring, MD, USA). The final tissue set consisted of four
blocks each containing 116–306 tumour sample cores for a total of
902 cores (Figure 1). The presence of DCIS in the arrayed samples
was verified on haematoxylin–eosin-stained sections.
Immunohistochemistry
Table 1 presents all antibodies, dilutions, incubation times, and
antigen-retrieval methods used. Tissue microarray blocks were cut
with a microtome into 4mm sections that were mounted on poly-L-
lysine-coated glass slides and processed for immunohistochem-
istry. After deparaffinisation and rehydration, unspecific binding
was blocked. Then, antigen retrieval by different pretreatment
methods was followed by incubation with the primary antibody.
After detection, sections were counterstained with haematoxylin.
Appropriate negative (the first antibody was either omitted or
replaced by non-immune rabbit IgG diluted to the same
concentration as the first antibody) and positive (as shown in
Table 1) controls were used throughout. Additionally, DCIS-TMA
sections were stained for ER, PR and Her-2/neu by standard
immunohistochemical methods as described previously (Wu ¨lfing
et al, 2003b).
Quantification
Semiquantitative analysis of staining results from 902 tissue array
cores was performed by two investigators in a blind-trial fashion
without knowing the histopathological data for the corresponding
case. Depending on the staining procedure varying numbers of
tissue cores were detached, others did not contain a sufficient
number of tumour cells. Also, if precise diagnosis of DCIS on the
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some cases could not be analysed.
For evaluation of bFGF-R1, ET-1, ETAR, and ETBR expression,
intensity of the cytoplasmic immunostaining was scored semi-
quantitatively on a four-tiered scale (negative¼0, weak¼1þ,
moderate¼2þ, strong¼3þ). We defined samples with a
moderate (2þ) or strong (3þ) cytoplasmic immunostaining
intensity to have an elevated expression of this marker and thus to
be ‘positive’, respectively (Wu ¨lfing et al, 2004b). A similar score
was used for VEGF-C and Flt-4, both showing a cytoplasmic and
nuclear immunostaining, and for KDR expression, which was
primarily observed in the cytoplasm but additionally showed a
staining of the cell membranes. For Flt-1, the cytoplasmic
immunostaining intensity was classified from 0 (negative) to 2þ
(moderate). Cases scored as X1þ were considered to be Flt-1
positive. Expression of bFGF and VEGF-A was characterised as a
negative or positive reaction according to both the intensity of the
immunostaining and the percentage of stained tumour cells.
Samples were judged to be positive if X10% of the tumour cells
showed moderate or strong cytoplasmic immunoreaction (De Jong
et al, 1998a). Her-2/neu staining was scored 0 (absent) to 3þ
(maximum cytomembranous staining), with a score X2þ
considered Her-2/neu-positive. ER and PR scores were calculated
as the percentage of positively stained nuclei. ER and PR status
were defined positive when X10% nuclei stained positively.
Data analysis
Staining results for the angiogenic and lymphangiogenic markers
were correlated with results for ER, PR, and Her-2/neu, as well as
with the nuclear grading of DCIS. According to the clinical
practice, low-grade and intermediate-grade cases were taken
together as ‘non-high-grade’ as opposed to the poorly differen-
tiated ‘high-grade’ DCIS. Correlations were tested for statistical
significance by cross-tables, applying Pearson’s w
2 test and Fishers’
exact test (SPSS 10.0). Differences between the groups of DCIS with
vs DCIS without an invasive carcinoma, as well as correlations
between coexistent DCIS and the respective invasive component
were also tested using w
2 test.
RESULTS
Immunohistochemistry of the DCIS specimens
Detailed staining results are depicted in Table 2. In the majority of
cases, tumour cells of DCIS showed expression of Flt-4, bFGF-R1,
VEGF-C, and ETAR, whereas Flt-1 and bFGF expression was rarely
observed. A positive immunoreaction for KDR, ET-1, VEGF-A, and
ETBR in the tumour cells was present in a varying number of
samples. The following immunohistochemical staining patterns of
DCIS were observed:
Vascular endothelial growth factor-A and VEGF-receptors
1 (Flt-1) and 2 (KDR)
Vascular endothelial growth factor-A: A positive immunoreaction
for VEGF-A was observed in about half of the DCIS samples. Most
cases presented with a faint or moderate cytoplasmic staining of
tumour cells (Figure 2C). Normal glandular cells were negative for
VEGF-A, while myoepithelial cells stained positively. The stromal
and connective tissue was mostly negative for VEGF-A.
Flt-1: Expression of Flt-1 in the tumour cells was found in very
few cases of DCIS (16.1%). Flt-1-positive cells showed a finely
granular staining of the cytoplasm (Figure 2D). The peritumoral
stroma often stained positively in Flt-1 positive cases. Normal
glandular cells were Flt-1-negative.
KDR: About half of the DCIS cases (53.5%) were considered to
be KDR-positive. KDR features a strong cytoplasmic staining
(Figure 2E). Normal glandular cells usually stained positively,
while stroma and connective tissue remained negative.
Vascular endothelial growth factor-C and VEGF-receptor 3
(Flt-4)
Vascular endothelial growth factor-C: In all, 88% of DCIS showed
intense staining and were considered to be VEGF-C-positive.
Expression of VEGF-C protein was observed in the cytoplasm of
tumour cells (Figure 2F). Little or no staining for VEGF-C was
observed in normal breast epithelium. Stromal and connective
tissues were VEGF-C negative.
Flt-4: For Flt-4, a strong staining of tumour cells was observed in
most cases (95.4%) (Figure 2G). Also, normal glandular cells were
often positive, while stromal and connective tissues were Flt-4-
negative.
Basic fibroblast growth factor and bFGF receptor
Basic fibroblast growth factor: Positive nuclear staining of tumour
cells with bFGF was present in only a few cases (12.3%). In a small
proportion of these positive cases, also a faint cytoplasmic staining
was observed (Figure 2A). Normal glandular cells often showed
immunoreaction for bFGF, while the stroma generally was bFGF-
negative.
Basic fibroblast growth factor-R1: Almost all DCIS (94.4%)
showed a strong and homogenous cytoplasmic expression of
bFGF-R1 in the tumour cells (Figure 2B); in few cases, also a
nuclear staining was observed. In bFGF-R1-positive cases, stromal
cells often exhibited a faint staining, too, while normal glandular
cells generally were moderately positive.
Figure 1 Tissue microarray. (A) Picture of a TMA; (B) stained section of
a TMA.
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Species Pretreatment Dilution Incubation times Detection Pab source Positive control
Growth factors
VEGF-A Rabbit Poly PK (10min) 1:15 25min PAb,
20min Link AP,
20min Strept AP,
2*8min modified ‘Neufuchsin’
LSAB/AP Santa Cruz Inflammatory tissue
VEGF-C Rabbit Poly S (35min) 1:25 25min PAb,
20min Link AP,
20min Strept AP,
2*8min modified ‘Neufuchsin’
LSAB/AP Santa Cruz Inflammatory tissue
bFGF Rabbit Poly MW 2 7min (450W) 1:2000 30min Dako Blocking Solution,
210min PAb at 371C,
30min Bridge-Ab at 231C,
30min 2P
ndP Bridge-Ab at 231C
APAAP Santa Cruz Inflammatory tissue
ET-1 Mouse MAb S (35min) 1:500 25min PAb,
20min Link AP,
20min Strept AP,
2*8min DAB
LSAB/HRP Affinity BioReagents Ovarian carcinoma
Receptors
Flt-1 (VEGFR-1) Rabbit Poly MW 2 7min (450W) 1:400 30min Dako Blocking Solution,
210min PAb at 371C,
30min Bridge-Ab at 231C,
30min 2P
ndP Bridge-Ab at 231C
APAAP Santa Cruz Inflammatory tissue
KDR (VEGFR-2) Mouse MAb MW 2 7min (450W) 1:400 30min Dako Blocking Solution,
210min PAb at 371C,
30min Bridge-Ab at 231C,
30min 2P
ndP Bridge-Ab at 231C
APAAP Santa Cruz Inflammatory tissue
Flt-4 (VEGFR-3) Rabbit Poly S (35min) 1:400 25min PAb,
20min secondary Agent (Link AP),
20min tertiary Agent (Strept AP),
2*8min modified ‘Neufuchsin’
LSAB/AP Santa Cruz Inflammatory tissue
bFGF-R1 Rabbit Poly MW 2 7min (450W) 1:400 30min Dako Blocking Solution,
210min PAb at 371C,
30min Bridge-Ab at 231C,
30min 2P
ndP Bridge-Ab at 231C
APAAP Santa Cruz Inflammatory tissue
ETAR Sheep MAb Reveal 5min; H2O 5min; Aurion BSA (1:30) 30min 1:800 25min PAb,
60min RAS (1 :25) at 231C,
60min Envision Detection Kit at 231C
LSAB/HRP Alexis Prostate carcinoma
ETBR Sheep MAb S (35min) 1:100 25min PAb,
20min secondary Ab (Rabbit-Anti-Sheep),
20min Link AP, 20min Strept AP,
2*8min DAB
LSAB/HRP Alexis Smooth muscle tissue
bFGF¼basic fibroblast growth factor; VEGF¼vascular endothelial growth factor; ET¼endothelin; R¼receptor; Flt¼fms-like tyrosine kinase; KDR¼kinase domain receptor; MAb¼monoclonal antibody; Poly¼polyclonal antibody;
PAb¼primary antibody; MW¼microwave; Citr.¼citrate (pH 6.0); WB¼waterbath; S¼steamer; PK¼proteinase k; o/n¼overnight; AP¼alcalic phosphatase; Strept¼labelled streptavidin; DAB¼3,3-diaminbenzidine;
LSAB¼labelled streptavidin biotin; HRP¼horseradish peroxidase; APAAP¼alcalic phosphatase anti-alcalic phosphatase. Santa Cruz Biotechnology Inc., Santa Cruz, USA. Affinity BioReagents, Golden, CO, USA. Alexis, Lausen,
Switzerland.
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Molecular DiagnosticsEndothelin-axis
Positive cytoplasmic staining of tumour cells was observed for ET-
1 in 48.4%, for ETAR in 76.4%, and for ETBR in 37.7% of cases
(Figure 2 H–J). Normal glandular cells were mostly negative; in
ET-positive cases, occasionally a weak staining of stromal
components was present.
Autocrine loops
Expression patterns in DCIS were screened for cases in which the
receptor and ligand are both expressed in the same cells,
suggesting potential autocrine loops. Possible autocrine loops
were observed for all receptor/ligand combinations in varying
numbers of cases (Table 3). Coexpression of ligand and receptor in
the tumour epithelium was most frequently found for the VEGF-C/
Flt-4 combination (87% of cases), followed by the combinations of
VEGF-C/KDR (51%), ET-1/ETAR (37%), ET-1/ETBR (26%), and
VEGF-A/KDR (25%).
Association of angiogenic markers with histopathological
features
The following associations between expression of angiogenic
markers and other histopathological parameters were observed:
ETAR and ETBR expression correlated with ER-negative DCIS
(P¼0.017 and Po0.001, respectively). In contrast, bFGF expres-
sion was associated with ER expression (P¼0.080), PR expression
(P¼0.003), lack of Her-2/neu expression (P¼0.013), and with
non-high-grade DCIS (P¼0.005). For Flt-1, a trend towards a
negative correlation with Her-2/neu expression was observed
(P¼0.097). No further associations between angiogenic markers
and histopathological features examined were found.
Table 2 Expression of growth factors and their receptors in tumour cells of DCIS (n (%) of evaluable cases with positive immunoreaction)
Antigen Total Pure DCIS Coexistent DCIS P
a
Growth factors
VEGF-A 80/175 (45.7%) 40/88 (45.5%) 40/87 (46%) NS
VEGF-C 152/172 (88.4%) 78/80 (97.5%) 74/92 (80.4%) Po0.001
bFGF 20/163 (12.3%) 11/78 (14.1%) 9/85 (10.6%) NS
ET-1 78/161 (48.4%) 32/75 (42.7%) 46/86 (53.5%) NS
Growth factor receptors
VEGFR-1 (Flt-1) 27/168 (16.1%) 2/79 (2.5%) 25/89 (28.1%) Po0.001
VEGFR-2 (KDR) 84/157 (53.5%) 47/75 (62.7%) 37/82 (45.1%) P¼0.028
VEGFR-3 (Flt-4) 165/173 (95.4%) 81/82 (98.8%) 84/91 (92.3%) P¼0.043
bFGF-R1 151/160 (94.4%) 77/80 (96.3%) 74/80 (92.5%) NS
ETAR 126/165 (76.4%) 69/81 (85.2%) 57/84 (67.9%) P¼0.009
ETBR 60/159 (37.7%) 28/79 (35.4%) 32/80 (40%) NS
NS¼nonsignificant.
aw
2 test (pure DCIS versus coexistent DCIS).
Figure 2 Ductal carcinoma in situ specimens with representative immunohistochemical staining patterns for (upper row) bFGF (A), bFGF-R1 (B), VEGF-
A( C), Flt-1 (D), KDR (E), and (lower row) VEGF-C (F), Flt-4 (G), ET-1 (H), ETAR( I), ETBR( J).
Table 3 Coexpression of ligand and respective receptor in the same
DCIS specimen indicating potential autocrine loops
Ligand/Receptor n/total (%)
VEGF-A/Flt-1 13/166 (7.8%)
VEGF-A/KDR 36/147 (24.5%)
VEGF-C/Flt-4 143/165 (86.7%)
VEGF-C/KDR 78/152 (51.3%)
bFGF/bFGF-R1 17/163 (10.4%)
ET-1/ETAR 60/161 (37.3%)
ET-1/ETBR 42/161 (26.1%)
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coexisting invasive carcinoma
Comparing the expression of angiogenic markers between the
groups of DCIS with (n¼104) vs DCIS without (n¼96) coexisting
invasive carcinoma revealed that expression of VEGF-C, KDR, Flt-
4, and ETAR was significantly more frequent in pure DCIS than in
DCIS with an adjacent invasive carcinoma (Table 2). These
differences between both DCIS groups were significantly more
pronounced in the subgroup of non-high-grade DCIS as compared
with high-grade DCIS (Table 4). In contrast, Flt-1 was significantly
higher expressed in the group of DCIS with an adjacent invasive
carcinoma irrespective of nuclear grading (Tables 2 and 4).
To evaluate whether these different expression patterns of
angiogenic markers between pure and coexistent DCIS merely
reflect an unequal distribution of DCIS with respect to histopatho-
logical and clinical features between both groups, possible
associations with nuclear grading, ER-, PR-, and Her-2/neu-status
and patients’ age were analysed. As shown in Table 5, no
significant differences were observed between both groups with
respect to these parameters.
Correlations between in situ and invasive carcinoma
To assess whether expression of classic histopathological factors
and angiogenic markers in coexistent DCIS is determined by
expression patterns in the respective invasive carcinomas, staining
results for the in situ and the invasive (IBC) components of each
patient in the coexistent DCIS group were compared. Among the
angiogenic factors, we focused on those which were differentially
expressed in the groups of pure and coexistent DCIS. Analysis of
ETAR (ETAR-positive; DCIS: 67.9% vs IBC: 65.5% of cases), VEGF-
C (VEGF-C positive; DCIS: 80.4% vs IBC: 88.6%), Flt-4 (Flt-4
positive; DCIS: 92.3% vs IBC: 93.3%), and Her-2/neu (Her-2/neu
positive; DCIS: 21.9% vs IBC: 16.4%) expression revealed a similar
frequency of positive staining in the in situ and the invasive
carcinomas. In contrast, expression of ER (ER-positive; DCIS:
26.9% vs IBC: 61.5% of cases), PR (PR-positive; DCIS: 35.1% vs
IBC: 48.1%), Flt-1 (Flt-1 positive; DCIS: 28.1% vs IBC: 44.2%), and
Table 4 Expression of growth factors and growth factor receptors stratified for nuclear grading
Factor Nuclear grade Pure DCIS Coexistent DCIS P (v
2 test)
Growth factorsU
VEGF-A Non-high-grade
a 25/55 (45.5%) 17/35 (48.6%) NS
High-grade 15/33 (45.5%) 21/49 (42.9%) NS
VEGF-C Non-high-grade 50/50 (100%) 27/37 (73%) Po0.001
High-grade 28/30 (93.3%) 44/52 (84.6%) NS
bFGF
b Non-high-grade 10/51 (19.6%) 6/35 (17.1%) NS
High-grade 1/27 (3.7%) 2/47 (4.3%) NS
ET-1 Non-high-grade 21/48 (43.8%) 16/34 (47.1%) NS
High-grade 11/27 (40.7%) 29/49 (59.2%) NS
Receptors
Flt-1 (VEGFR-1) Non-high-grade 1/50 (2%) 13/36 (36.1%) Po0.001
High-grade 1/29 (3.4%) 12/50 (24%) P¼0.018
KDR (VEGFR-2) Non-high-grade 33/50 (66%) 12/34 (35.3%) P¼0.006
High-grade 14/25 (56%) 23/45 (51.1%) NS
Flt-4 (VEGFR-3) Non-high-grade 50/50 (100%) 33/37 (89.2%) P¼0.017
High-grade 31/32 (96.9%) 48/51 (94.1%) NS
bFGF-R1 Non-high-grade 47/49 (95.9%) 29/32 (90.6%) NS
High-grade 30/31 (96.8%) 43/46 (93.5%) NS
ETAR Non-high-grade 44/53 (83%) 22/36 (61.1%) P¼0.020
High-grade 25/28 (89.3%) 32/45 (71.1%) NS
ETBR Non-high-grade 20/49 (40.8%) 12/32 (37.5%) NS
High-grade 8/30 (26.7%) 18/45 (40%) NS
NS¼nonsignificant.
aNon-high-grade¼low + intermediate grade DCIS.
bLogistic regression showed a significant correlation between bFGF expression and grading (P¼0.009).
Table 5 Distribution of clinical and histopathological characteristics in
the subgroups of pure vs coexistent DCIS
Parameter Pure DCIS Coexistent DCIS P
Patients’ age (years) 60.5713.6 57.3714.4 NS
Estrogen receptor
Negative 46/70 (65.7%) 57/78 (73.1%) NS
Positive 24/70 (34.3%) 21/78 (26.9%)
Progesterone receptor
Negative 41/69 (59.4%) 50/77 (64.9%) NS
Positive 28/69 (40.6%) 27/77 (35.1%)
Her-2/neu
Negative 57/73 (78.1%) 57/73 (78.1%) NS
Positive 16/73 (21.9%) 16/73 (21.9%)
Nuclear grade
Non-high-grade 57/96 (59.4%) 46/101 (45.5%) NS
High-grade 39/96 (40.6%) 55/101 (54.5%)
NS¼nonsignificant.
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more frequent in the invasive component than in the coexistent in
situ lesion (each Po0.05). Moreover, a close concordance was
observed with respect to nuclear grading of the in situ and
histological grading of the respective invasive component (Kruskal
Wallis test; Po0.001).
DISCUSSION
Tumour progression is characterised by the uncontrolled growth
of tumour cells which may then invade the surrounding host tissue
and metastasise to distant organs. The growth of small tumours is
initially limited by the distance beyond which nutrients and
oxygen can diffuse. Thus, angiogenesis is known to be a
prerequisite for tumour growth beyond a few (1–3) mm
3 in size.
Following the ‘angiogenic switch’ of a tumour, rapid tumour
growth, local invasion, and, ultimately, metastasis occur (Folkman
et al, 1989). The identification of an increased vascular density
around DCIS in a number of studies (Guidi et al, 1994; Engels et al,
1997; Teo et al, 2003) and the observed association of higher
vascularity in DCIS with invasive recurrence (Teo et al, 2003) have
lead to the hypothesis that an angiogenic switch in DCIS may
contribute to the transformation from in situ to invasive
carcinoma. In DCIS, two distinct vascular patterns have been
described: (1) a diffuse increase of MVD in the stroma and (2) an
increase in the number of periductal microvessels, the latter
presumably due to the direct release of angiogenic factors by
neoplastic cells within the ducts (Guidi et al, 1994; Engels et al,
1997).
Angiogenesis as a multistep process is controlled by various
positive and negative regulatory signals. Endogenous proangio-
genic factors that could have an impact on regulation of
angiogenesis in DCIS are, for example, VEGF, bFGF, ET-1, and
their respective receptors; the sole exception to this is VEGFR-1
(Flt-1) which is supposed to mediate antiangiogenic effects. In the
present study, we analysed expression of several angiogenic as well
as lymphangiogenic growth factors and their receptors in a large
series of DCIS to evaluate potential associations with established
histopathological characteristics and to assess whether there are
different expression patterns between the groups of DCIS with
(n¼104) and without (n¼96) coexistent invasive carcinoma.
Vascular endothelial growth factor-A and its receptor KDR were
expressed in the tumour cells of about half the cases, whereas Flt-1
expression was rarely observed (16%). Expression of VEGF-A in
tumour cells of DCIS has been reported previously and was
demonstrated to correlate with the degree of angiogenesis (Guidi
et al, 1997). However, to the best of our knowledge, the present
publication is the first to describe expression of VEGF-A receptors,
KDR and Flt-1, in DCIS. In general, KDR is recognised as the
predominant signal transducer of tumour angiogenesis, whereas
Flt-1 (and especially its soluble form) is a negative regulator of
VEGF availability (Ferrara et al, 2003). In invasive breast cancer,
expression of Flt-1 and KDR has been observed in 44 and 38% of
cases, respectively (De Jong et al, 1998a). Our finding of a rare Flt-
1 expression as opposed to a considerably higher rate of KDR
expression may therefore point to a presumably increased
angiogenic activity in DCIS paralleled by the downregulation of
antiangiogenic receptors while the so-called angiogenic switch.
In this study, VEGF-C and Flt-4, established mediators of
angiogenesis (Cao et al, 1998; Valtola et al, 1999) and in particular
of lymphangiogenesis (Jeltsch et al, 1997; Kinoshita et al, 2001),
were expressed in the tumour cells of the majority of DCIS
specimens (88 and 95%, respectively). For invasive breast cancer, a
similar rate of VEGF-C-positive cases has been reported previously
(Nakamura et al, 2003). To date, there is only one other study
published investigating VEGF-C expression in a small series of
DCIS (n¼8). In that series, VEGF-C was secreted by the
intraductal carcinoma cells and was suggested to act as a growth
factor for Flt-4-positive periductal blood vessels and (less
evidently) for lymphatic vessels (Valtola et al, 1999). This
implicates an association of Flt-4 and its ligand VEGF-C with
angiogenesis in DCIS. However, there are no published data on Flt-
4 expression in tumour cells of DCIS yet. Our findings on the
presence of Flt-4 expression in the majority of intraductal tumour
cells also suggest an autocrine growth-stimulatory pattern of
VEGF-C via Flt-4 as described for cervical cancer (Van Trappen
et al, 2003). However, a recently published study of Vleugel et al
(2004) demonstrated that no intralesional increase in lymph vessel
density occurs during breast carcinogenesis. Nonetheless, in
general it is without doubt that the spread of tumour cells via
the lymphatic system is one of the major causes of metastasis and
consecutively tumour-related death. Therefore, the lymphangio-
genic effects of intratumorously synthesised VEGF-C may be
explained by a perilesional induction of stromal lymphangiogen-
esis.
In the present study, bFGF expression was rarely observed in
DCIS (12%), whereas almost all DCIS cases showed bFGF-R
expression. To date, there are no further data available in the
literature on expression of bFGF and its receptors in DCIS. Our
observation on the small proportion of bFGF-expressing DCIS
specimens strongly contrasts reports on a higher rate (44%) of
bFGF expression in invasive breast carcinomas (De Jong et al,
1998a). This may reflect an intermediate position of DCIS between
normal breast tissue and invasive breast cancer, the latter
reportedly showing increased bFGF levels as compared to
nonmalignant tissue (Smith et al, 1999). Nonetheless, in DCIS,
we observed an association between higher bFGF expression with
favourable prognostic criteria (low grade, positive steroid hor-
mone receptor status, and lack of Her-2/neu expression), as
described earlier for invasive breast cancer (Smith et al, 1999).
This is also in good agreement with survival data in patients with
invasive breast carcinomas in which bFGF expression was found to
correlate with a longer disease-free interval (Colomer et al, 1997).
Thus, although it has been shown that bFGF expression is related
to higher angiogenic activity (De Jong et al, 1998b), bFGF may
represent an indicator for invasive breast carcinomas with
favourable prognosis as well as for DCIS lesions less likely to
progress to invasive breast cancer.
In our study, ET-1 was expressed in the tumour cells of 48%.
However, the ET receptors, ETAR and ETBR, showed an unequal
distribution: ETAR was present in the majority (76%) of DCIS
whereas ETBR expression was found significantly less frequently
(38%). We have previously shown that expression of the ET-axis is
increased in invasive breast cancer and that, in particular, ETAR
expression correlates with more aggressive tumour types and poor
survival (Wu ¨lfing et al, 2003a). Moreover, we found a significant
positive correlation between expression of the ET-axis and
vascularity as well as VEGF expression of breast carcinomas
(Wu ¨lfing et al, 2004b). Thus, the ET-axis and especially ETAR may
represent a marker of malignant and angiogenic activity in breast
cancer. In another study comparing expression of the ET-axis in a
series (n¼88) of invasive breast carcinomas, concomitant DCIS,
and normal breast tissue, we demonstrated a stepwise increase of
ET-1 and ETAR expression with disease progression, suggesting
that expression of these proteins correlates with the acquisition of
malignant potential and invasive behaviour (Wu ¨lfing et al, 2004a).
The present study also highlights the potential role of ETAR
expression in breast carcinogenesis. These findings may have
clinical relevance since ETAR represents a potential target for
antiangiogenic and antitumorigenic therapy (Nelson et al, 2003). It
is therefore conceivable that the administration of selective ETAR
antagonists may prevent transformation from intraductal to
invasive breast cancer.
Ductal carcinoma in situ is heterogeneous in its histology and
clinical presentation, and so far there is no generally accepted
DCIS and angiogenesis
PW u ¨lfing et al
1726
British Journal of Cancer (2005) 92(9), 1720–1728 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smodel to predict progression to invasive carcinoma. Pure DCIS
does not have the potential to metastasise and thereby leading to
death. Therefore, the particular importance of DCIS is the risk of
developing to invasive carcinoma.
In this study, comparative analysis of expression of these growth
factors and their respective receptors in the groups of pure DCIS vs
coexistent DCIS revealed that expression of proangiogenic factors
such as VEGF-C, KDR, Flt-4, and ETAR was significantly more
common in pure DCIS than in DCIS with an adjacent invasive
carcinoma (coexistent DCIS). Conversely, Flt-1 as a negative
regulator of VEGF availability and thus being regarded as an
antiangiogenic receptor was expressed significantly more fre-
quently in the group of coexistent breast carcinomas. These results
indicate a higher angiogenic activity in DCIS without coexistent
invasive carcinoma (pure DCIS). Several explanations are feasible
for this rather unexpected finding: Our data, demonstrating
quantitative differences between expression of angiogenic factors,
suggest a biological difference among the groups of (a) pure DCIS
and (b) DCIS with concomitant invasive carcinoma. This is
consistent with findings from Teo et al (2002) describing a
different vascular density and phenotype in pure DCIS vs DCIS
associated with invasive carcinoma, the latter showing significantly
greater numbers of CD34þ and CD141þ vessels and fewer
staining for FVIII (Teo et al, 2002). Besides distinct vascular
profiles in pure and coexistent DCIS, that study also showed a
significant negative correlation between vascular density and the
extent of necrosis of the tumour, and a correlation between
vascular density and the nuclear grade was noted, being highest in
the intermediate grade DCIS (Teo et al, 2002). The latter is also in
agreement with our observation that the association of the
proangiogenic growth factors and receptors with pure DCIS was
considerably more pronounced in the subgroup of non-high-grade
DCIS as compared with high-grade DCIS. This could indicate that
the group of non-high-grade DCIS without coexistent invasive
carcinoma is particularly angiogenic. Our results on different
expression patterns of angiogenic factors in non-high-grade as
opposed to high-grade DCIS is also compatible with the notion
that distinct progression routes exist in the evolution from DCIS to
invasive breast cancer (Buerger et al, 1999; Mommers et al, 2001).
Also, the similarity in expression of ETAR, VEGF-C, Flt-4, and Her-
2/neu between the in situ and the concomitant invasive carcinomas
and the observed close concordance with respect to nuclear
grading between both components is in agreement with previous
reports on different lines of genetic evolution of invasive breast
cancer (Buerger et al, 1999, 2001; Mommers et al, 2001).
With respect to our findings, it is conceivable that determination
of VEGF-C, ETAR, KDR, and Flt-4 expression may facilitate
discrimination of a more angiogenic subset within the group of
non-high-grade DCIS without coexistent invasive carcinoma.
Among non-high-grade DCIS, this more angiogenic group may
have a higher probability of recurrence or of progression to
invasiveness and thus presumably necessitates a risk-adapted
therapy. This is of major clinical importance since approximately
half of the local recurrences after treatment for a primary DCIS are
invasive and no appropriate tumour marker is available yet that
would allow for prediction of recurrence. Moreover, during the last
years, antiangiogenic therapy for malignancies has been exten-
sively investigated, and many novel agents representing several
approaches to blocking tumour neovascularisation are in clinical
trials (Eskens, 2004).
In conclusion, this study showed expression of VEGF-C and its
receptor Flt-4, both representing lymphangiogenic growth factors,
in intraductal tumour cells of nearly all DCIS lesions. Furthermore,
most of the DCIS cases showed significant expression of various
angiogenic growth factors. Our data therefore indicate that in situ
carcinomas are capable of inducing angiogenesis and lymphan-
giogenesis. Moreover, we found a higher angiogenic activity in
DCIS without coexistent invasive carcinoma (pure DCIS) as
compared to DCIS with concomitant invasive carcinoma. This
association of angiogenic factors with pure DCIS was considerably
more pronounced in the subgroup of non-high-grade DCIS as
compared with high-grade DCIS. One can therefore assume from
these data that the group of non-high-grade DCIS without
coexistent invasive carcinoma is particularly angiogenic. Determi-
nation of these angiogenic markers in pure DCIS may therefore
facilitate discrimination of a more angiogenic subset with a
potentially higher risk of progression. This subset of patients could
benefit from a risk-oriented, targeted antiangiogenic therapy
which represents a potential strategy for prevention of progression
of DCIS to invasion.
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